Nevertheless, a low tumor-to-liver ratio observed in a study by Kunikowska et al. suggested that radiolabeled PSMA ligands may have a limited role in targeted radionuclide therapy of recurrent GBM (160). Here, FOLH1 is linked to neoplasm.